Next Generation Dx Summit features COVID-19 updates across four conferences: Enabling Point-of-Care Diagnostics, Point-of-Care Technologies, Advanced Diagnostics for Infectious Disease, and Diagnostics Reimbursement. Can't decide on a single program? We encourage program-hopping at the Next Generation Dx Summit to help attendees maximize their on-site experience.


track1-POCT tech

Enabling Point-of-Care Diagnostics

August 25-26, 2020
View Program


Geospatial “Hot Spots” Need Rapid Point-of-Care Diagnostics to Stop Highly Infectious Threats and Antimicrobial Resistance
Gerald Kost, MD, PhD, MS, FAACC, Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR); Emeritus Professor, School of Medicine, University of California, Davis

Rapid Development of Diagnostic Tests for New Threats: 2019 Novel Coronavirus Pneumonia (COVID-19) and Other Pathogens
Timothy Minogue, Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases

Point-of-Care Molecular Diagnostics for Disease Outbreak Settings: The Path to the Future
Rachel Spurbeck, PhD, Principal Research Scientist, Health Outcomes and Biotechnology Solutions, Battelle Memorial Institute

Point-of-Care Technologies

August 26-27, 2020
View Program


The Next Generation of Continuous Diagnostic Sensors: A Case Study on the Breakthroughs for Sweat Biosensing
Jason Heikenfeld, PhD, Vice President, Operations, Office of Innovation; Professor and Director, Novel Device Laboratory, University of Cincinnati

Engineering Biology for Diagnostic Solutions
William Blake, PhD, CTO, Sherlock Bioscience


Advanced Diagnostics for Infectious Disease

August 26-27, 2020
View Program

Presentations by:

DOD’s Pursuit of Pre-Symptomatic Non-Invasive Diagnostics
Edward Argenta, Science & Technology Manager, Biological & Chemical Technologies, Defense Threat Reduction Agency

The Biofire Pneumonia Panel: Does It Relate to Microbiological and Clinical Variables?
Kenneth Rand, MD, Medical Director, Clinical Microbiology Laboratory; Professor, Pathology and Medicine, University of Florida

The Challenges in Testing for COVID-19 and How do we Learn for the Next Pandemic
PANEL MODERATOR: Nathan Ledeboer, PhD, Professor and Vice Chair, Pathology and Medical Director, Medical College of Wisconsin

  • Supply shortages, what can labs and the government do to be better prepared in an era of just in time shipping
  • Regulatory changes, what changes are needed to ensure testing is not limited for the next pandemic?
  • Some foundations such as Gates and Rockefeller are considering developing surveillance networks
  • As we increasingly move to FDA cleared products, are we losing the ability to develop our own tests?
  • What is the role of NGS-based assays in mass surveillance
  • How do we solve the extraction challenge?
  • Test performance was a major issue in COVID-19, what can we learn?

Norman Moore, PhD, Director, Scientific Affairs, Abbott
Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children’s Hospital Los Angeles; Associate Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California
Matthew Binnicker, PhD, Consultant, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology; Vice Chair of Supply Chain Management, Department of Laboratory Medicine and Pathology; Vice Chair of Practice, Department of Laboratory Medicine/Pathology, Mayo Clinic
Emily Crawford, PhD, Scientist II, Infectious Disease Initiative, Chan Zuckerberg Biohu


Coverage and Reimbursement for Advanced Diagnostics

August 25-26, 2020
View Program


Coding for The Frontlines: Establishing CPT® Codes for Novel Coronavirus (SARS-CoV-2) Tests
Zach Hochstetler, Director, CPT Editorial and Regulatory Services, American Medical Association, AMA

PANEL DISCUSSION: Hot Button Issues in Dx Reimbursement

Danielle Scelfo, Senior Director, Health Policy and Reimbursement, Hologic, Inc.
Ester Stein, MBA, Director, Corporate Reimbursement, Government Affairs, Abbott Laboratories

Jim Almas, MD, Vice President and National Medical Director, Clinical Effectiveness, LabCorp
Marc Hartstein, Principal, Health Policy Alternatives
Julie Khani, President, American Clinical Laboratory Association


Speaker Proposal